|
Though gender diversity is crucial for getting medicine making right, we have to stop and ask ourselves if enough is being done to address the natural differences that exist within patient populations. Historical data shows that drugs affect men and women differently, but even some of the most recent drug trials, including those for COVID-19 vaccines, have failed to thoroughly consider the impact of sex on therapeutic efficacy. In this week’s newsletter, you’ll find commentary on the topic from Ann Taylor, Chief Medical Officer at AstraZeneca, who says, “Diversity in the drug development process [...] is not a ‘nice to do.’ It’s a business – and ethical – imperative.” For Taylor’s full perspective, check out the article below.
|
